Physician profile
Deepa Taneja
NPI 1548424252
$30,322.40
in general payments reported to CMS, 2019-2025
52 companies · $5,253 in 2025
The $5,253 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $7,753 · 2021: $12K · 2022: $1,777 · 2023: $1,679 · 2024: $1,451 · 2025: $5,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,826 · Consulting Fee: $2,543 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,826.40 |
| Consulting Fee | $2,542.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18,182.83 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $3,676.77 | 2019-2025 | |
| Novo Nordisk INC | $1,255.30 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $954.31 | 2019-2025 | Omnipod |
| Amgen INC. | $855.97 | 2019-2025 | Repatha, Tepezza, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $654.86 | 2020-2025 | Jardiance |
| Dexcom, INC. | $400.68 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $390.05 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $306.68 | 2021-2025 | Gvoke Hypopen, Keveyis |
| Corcept Therapeutics | $261.22 | 2020-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $251.60 | 2023-2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $245.98 | 2021-2025 | Unithroid |
| Esperion Therapeutics, INC. | $192.71 | 2021-2025 | Nexletol |
| Horizon Therapeutics Plc | $192.29 | 2021-2023 | Tepezza |
| Abbott Laboratories | $176.05 | 2020-2024 | Freestyle Libre |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $172.03 | 2024-2025 | Isturisa |
| Alexion Pharmaceuticals, INC. | $167.63 | 2025 | Strensiq |
| Ibsa Pharma INC. | $167.49 | 2022-2024 | Tirosint, Licart, Tirosint |
| Pfizer INC. | $166.50 | 2023-2024 | |
| Penumbra, INC. | $160.44 | 2022 | |
| Boston Scientific Corporation | $147.40 | 2023 | Watchman Access System |
| Abbvie INC. | $136.61 | 2020-2024 | Synthroid |
| Novartis Pharmaceuticals Corporation | $110.23 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $92.69 | 2020-2025 | Verquvo |
| Shire North American Group INC | $84.12 | 2019 | |
| Currax Pharmaceuticals LLC | $72.83 | 2024-2025 | Contrave |
| Ascensia Diabetes Care US INC. | $68.63 | 2023-2024 | |
| Sequel Med Tech, LLC | $61.16 | 2025 | Twiist |
| Averitas Pharma INC. | $53.88 | 2025 | Qutenza |
| Tandem Diabetes Care, INC. | $52.84 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $51.29 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $50.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $45.53 | 2021-2025 | Farxiga |
| Medtronic, INC. | $37.04 | 2023-2024 | Minimed 780g, Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $35.19 | 2025 | Arexvy, Shingrix |
| Grt US Holding, INC. | $33.41 | 2021 | |
| Tolmar, INC. | $33.07 | 2023-2025 | Jatenzo |
| Rhythm Pharmaceuticals, INC. | $31.76 | 2025 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $30.80 | 2020 | |
| Neurocrine Biosciences, INC. | $30.78 | 2025 | |
| Beta Bionics, INC. | $27.67 | 2023 | Ilet Bionic Pancreas |
| Angiodynamics, INC. | $26.98 | 2025 | Venacure 1470 Pro |
| Almatica Pharma LLC | $25.00 | 2024 | Teriparatide, Loreev Xr |
| Renalytix Ai, INC. | $23.39 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.76 | 2021 | |
| Radius Health, INC. | $19.59 | 2023 | Tymlos |
| Mannkind Corporation | $19.31 | 2021 | |
| Amryt Pharma Holdings Ltd | $16.51 | 2022 | |
| Medicure Pharma INC. | $13.81 | 2024 | Zypitamag |
| Acerus Pharmaceuticals Corporation | $13.13 | 2022 | |
| Vistapharm, INC. | $12.90 | 2021 | |
| Amarin Pharma, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Taneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.